Clinical Endoscopy (May 2022)

Epidemiology of early esophageal adenocarcinoma

  • Thuy-Van P. Hang,
  • Zachary Spiritos,
  • Anthony M. Gamboa,
  • Zhengjia Chen,
  • Seth Force,
  • Vaishali Patel,
  • Saurabh Chawla,
  • Steven Keilin,
  • Nabil F. Saba,
  • Bassel El-Rayes,
  • Qiang Cai,
  • Field F. Willingham

DOI
https://doi.org/10.5946/ce.2021.152
Journal volume & issue
Vol. 55, no. 3
pp. 372 – 380

Abstract

Read online

Background/Aims Endoscopic resection has become the preferred treatment approach for select early esophageal adenocarcinoma (EAC); however, the epidemiology of early stage disease has not been well defined. Methods Surveillance Epidemiology and End Results (SEER) data were analyzed to determine age-adjusted incidence rates among major epithelial carcinomas, including EAC, from 1973 to 2017. The percent change in incidence over time was compared according to tumor subtype. Early T-stage, node-negative EAC without metastasis was examined from 2004 to 2017 when precise T-stage data were available. Results The percent change in annual incidence from 1973 to 2017 was 767% for EAC. Joinpoint analysis showed that the average annual percent change in EAC from 1973 to 2017 was 5.11% (95% confidence interval, 4.66%–5.56%). The annual percent change appeared to plateau between 2004 and 2017; however, early EAC decreased from 2010 to 2017, with an annual percent change of –5.78%. Conclusions There has been a 7-fold increase in the incidence of EAC, which was significantly greater than that of the other major epithelial malignancies examined. More recently, the incidence of early EAC has been decreasing. Approximately one in five patients has node negative, potentially resectable early stage disease.

Keywords